Kiromic LLC

Lubbock, TX, United States

Kiromic LLC

Lubbock, TX, United States
SEARCH FILTERS
Time filter
Source Type

Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 report gives comprehensive insight on various clinical and non-clinical advancements in the global dendritic cell cancer vaccine market.  In recent years, dendritic cell cancer vaccines have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 53 dendritic cell cancer vaccines in clinical pipeline. Most of  the dendritic cell cancer vaccines are in preclinical phase followed by phase-II clinical trials. The recent advancement in in situ dendritic cell production from its progenitor cells, its maturation enabling processes and its delivery techniques has added to their advantage. They are also known to generate memory T cells which could produce a heightened secondary immune response for future encounters with the tumor cells in case of tumor progression. As cancer cells are known to evade immune response by triggering regulatory T cells suppressing the immune system, dendritic cells come to the rescue as it antagonistically acts on immune checkpoint inhibitors like CLAT4 and CD25 mediated immune pathways, thereby breaking the host's immune tolerance. As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market. Even though some technical concerns existed regarding in situ production of dendritic cells due to its low concentration in peripheral tissues, it has been successfully overcome with engineered dendritic cells which could now be produced in large number for mass scale vaccination programs. Simultaneous administration of regulating factors which facilitate dendritic cell survival and immune-modulator function holds the key for increased efficiency of cancer vaccine based on dendritic cell, the superspecialised sentinels of cancer immunotherapy, the title it truly deserves. Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 Highlights: - Global Dendritic Cell Cancer Vaccine Market Overview - Assessment of Dendritic Vaccines with Other Therapeutic Regimens - Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase - Marketed Dendritic Cell Vaccines Clinical Insight - Dendritic Cells Mechanizing Immune Response - Future Growth Opportunities Key Topics Covered: 1. Advent of Dendritic Vaccine in Oncology 2. Cataloging towards Dendritic Cells 3. Dendritic Cells Mechanizing Immune Response 3.1 Antigen Appearance Leads to Cellular Immune Responses 3.2 Stacking of Distinct Antigens over Dendritic Cells 3.3 Dendritic Cells Source & Subsets 3.4 Trail towards Maturation 3.5 Stimulation Initiates Maturation 3.6 Migration to Lymph Node 3.7 Precision of Dendritic Cells Vaccination 3.8 Illustrations of Clinical Results among Varied Cancer 3.9 Quality Control 3.10 Immune Monitoring 4. Equipping Dendritic Cell Vaccines 4.1 Cross Presentation of CD4 T-CD8 T Cells 4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ 4.3 Strategies to Activate NKT Cells 5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens 5.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies 5.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine 5.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine 5.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine 6. Dendritic Cell Cancer Vaccine Market & Clinical Insight 6.1 Some Trends Involving Dendritic Cells Cancer Vaccination 6.2 Dendritic Cell Cancer Vaccine Pipeline Overview 7. Undercurrents of Dendritic Cancer Vaccine Growth 8. Challenging Milieu for Dendritic Cancer Vaccine 9. Prospective Trajectories for Future 10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase 10.1 Research 10.2 Preclinical 10.3 Clinical 10.4 Phase I 10.5 Phase I/II 10.6 Phase II 10.7 Phase II/III 10.8 Phase III 11. Marketed Dendritic Cell Vaccines Clinical Insight 11.1 Sipuleucel-T (Provenge) 11.2 Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC & CreaVax-RCC) 11.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical 12. Competitve Landscape 12.1 3M Company 12.2 Activartis 12.3 Argos Therapeutics 12.4 Batavia Bioservices 12.5 Bellicum Pharmaceuticals 12.6 Creagene 12.7 DanDrit Biotech 12.8 DCPrime 12.9 Dendreon Corporation 12.10 Elios Therapeutics 12.11 ImmunoCellular Therapeutics 12.12 Immunicum 12.13 Kiromic 12.14 Medigene 12.15 Merck 12.16 Northwest Biotherapeutics 12.17 Glaxo Smith Kline 12.18 ImmunoCellular Therapeutics 12.19 SOTIO 12.20 Tella Incorporation 12.21 Theravectys 12.22 Vaxil BioTherapeutics For more information about this report visit http://www.researchandmarkets.com/research/dvngj2/global_dendritic To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-dendritic-cell-cancer-vaccine-market--clinical-trials-outlook-to-2023---research-and-markets-300473031.html


Cao M.,Central Arkansas Veterans Healthcare System | Theus S.A.,Central Arkansas Veterans Healthcare System | Straub K.D.,Central Arkansas Veterans Healthcare System | Figueroa J.A.,Kiromic LLC | And 4 more authors.
Journal of Translational Medicine | Year: 2015

Inflammation is a key etiologic component in atherogenesis. Previously we demonstrated that adeno-associated virus (AAV) 2/8 gene delivery of Netrin1 inhibited atherosclerosis in the low density lipoprotein receptor knockout mice on high-cholesterol diet (LDLR-KO/HCD). One important finding from this study was that FOXP3 was strongly up-regulated in these Netrin1-treated animals, as FOXP3 is an anti-inflammatory gene, being the master transcription factor of regulatory T cells. These results suggested that the FOXP3 gene might potentially be used, itself, as an agent to limit atherosclerosis. To test this hypothesis AAV2/8 (AAV)/hFOXP3 or AAV/Neo (control) gene therapy virus were tail vein injected into the LDLR-KO/HCD animal model. It was found that hFOXP3 gene delivery was associated with significantly lower HCD-induced atherogenesis, as measured by larger aortic lumen cross sectional area, thinner aortic wall thickness, and lower aortic systolic blood velocity compared with Neo gene-HCD-treated controls. Moreover these measurements taken from the hFOXP3/HCD-treated animals very closely matched those measurements taken from the normal diet (ND) control animals. These data strongly suggest that AAV/hFOXP3 delivery gave a robust anti-atherosclerosis therapeutic effect and further suggest that FOXP3 be examined more stringently as a therapeutic gene for clinical use. © 2015 Cao et al.


Zhu H.,Central Arkansas Veterans Healthcare System | Cao M.,Central Arkansas Veterans Healthcare System | Figueroa J.A.,Texas Tech University Health Sciences Center | Figueroa J.A.,Kiromic LLC | And 6 more authors.
Journal of Translational Medicine | Year: 2014

Background: Inflammation is a key etiologic component in atherogenesis and transforming growth factor beta 1 (TGFβ1) is a well known anti-inflammatory cytokine which potentially might be used to limit it. Yet TGFβ1 is pleiomorphic, causing fibrosis, cell taxis, and under certain circumstances, can even worsen inflammation. SMAD3 is an important member of TGFβ1′s signal transduction pathway, but is a fully intracellular protein.Objectives: With the hope of attenuating TGFβ1′s adverse systemic effects (eg. fibrosis) and accentuating its anti-inflammatory activity, we proposed the use of human (h)SMAD3 as an intracellular substitute for TGFβ1.Study design: To test this hypothesis adeno-associated virus type 2/8 (AAV)/hSMAD3 or AAV/Neo (control) was tail vein injected into the low density lipoprotein receptor knockout (LDLR-KO) mice, then placed on a high-cholesterol diet (HCD).Results: The hSMAD3 delivery was associated with significantly lower atherogenesis as measured by larger aortic cross sectional area, thinner aortic wall thickness, and lower aortic systolic blood velocity compared with Neo gene-treated controls. HSMAD3 delivery also resulted in fewer aortic macrophages by immunohistochemistry for CD68 and ITGAM, and quantitative reverse transcriptase polymerase chain reaction analysis of EMR and ITGAM. Overall, aortic cytokine expression showed an enhancement of Th2 response (higher IL-4 and IL-10); while Th1 response (IL-12) was lower with hSMAD3 delivery. While TGFβ1 is often associated with increased fibrosis, AAV/hSMAD3 delivery exhibited no increase of collagen 1A2 or significantly lower 2A1 expression in the aorta compared with Neo-delivery. Connective tissue growth factor (CTGF), a mediator of TGFβ1/SMAD3-induced fibrosis, was unchanged in hSMAD3-delivered aortas. In the liver, all three of these genes were down-regulated by hSMAD3 gene delivery.Conclusion: These data strongly suggest that AAV/hSMAD3 delivery gave anti-atherosclerosis therapeutic effect without the expected undesirable effect of TGFβ1-associated fibrosis. © 2014 Zhu et al.; licensee BioMed Central Ltd.


Arnaboldi F.,University of Milan | Menon A.,University of Milan | Menegola E.,University of Milan | Di Renzo F.,University of Milan | And 10 more authors.
International Reviews of Immunology | Year: 2014

Sperm protein 17 (Sp17) was originally identified in the flagellum of spermatozoa and subsequently included in the subfamily of tumor-associated antigens known as cancer-testes antigens (CTA). Sp17 has been associated with the motility and migratory capacity in tumor cells, representing a link between gene expression patterns in germinal and tumor cells of different histological origins. Here we review the relevance of Sp17 expression in the mouse embryo and cancerous tissues, and present additional data demonstrating Sp17 complex expression pattern in this murine model. The expression of Sp17 in embryonic as well as adult neoplastic cells, but not normal tissues, suggests this protein should be considered an "oncofetal antigen." Further investigations are necessary to elucidate the mechanisms and functional significance of Sp17 aberrant expression in human adult cells and its implication in the pathobiology of cancer. © 2014 Informa Healthcare USA, Inc.


Mirandola L.,Texas Tech University | Mirandola L.,Laura W Bush Institute For Womens Health | Nguyen D.D.,Texas Tech University | Nguyen D.D.,Laura W Bush Institute For Womens Health | And 14 more authors.
International Reviews of Immunology | Year: 2014

Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer. © 2014 Informa Healthcare USA, Inc.


Cobos C.,Texas Tech University | Figueroa J.A.,Texas Tech University | Figueroa J.A.,Laura W Bush Institute For Womens Health | Figueroa J.A.,Kiromic LLC | And 23 more authors.
International Reviews of Immunology | Year: 2014

Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela. © 2014 Informa Healthcare USA, Inc.


Grizzi F.,Humanitas Clinical and Research Center | Mirandola L.,Texas Tech University Health Sciences Center | Mirandola L.,Kiromic LLC | Qehajaj D.,Humanitas Clinical and Research Center | And 6 more authors.
International Reviews of Immunology | Year: 2015

The ability of immunotherapy to evoke successful antitumor immune responses has been well documented over the past decade. Despite abundant preclinical data, it is only with the recent approval by the Food and Drug Administration (FDA) of the drugs such as sipuleucel-T and ipilimumab that immunotherapy is finally being recognized as a viable alternative to traditional therapies for treatment of various cancers. Despite the ability of immunotherapy to elicit successful antitumor immune responses, its efficacy is hindered by several factors. Among these are the paucity of tumor-associated antigens (TAA) that can be used as effective targets and the systemic toxicities that often lead to treatment interruption. Indeed, such adverse effects, which can be immunological and/or parenchymal, can be particularly severe and even fatal to some patients. A family of TAA called cancer-testis antigens (CTA) has been identified and their encoding genes have been extensively investigated. CTA expression has been demonstrated in a variety of human cancer tissues, and at least 19 CTA have been found to elicit humoral and/or cellular immune responses in cancer patients. Here we discuss how CTA and immunotherapy will most likely play a major role in the cure of cancer in the light of cancer complexity. © 2015 Informa Healthcare USA, Inc.


Figueroa J.A.,Texas Tech University Health Sciences Center | Figueroa J.A.,Kiromic LLC | Reidy A.,Texas Tech University Health Sciences Center | Reidy A.,Kiromic LLC | And 25 more authors.
International Reviews of Immunology | Year: 2015

Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer. © 2015 Informa Healthcare USA, Inc.


Zhu H.,Medical Research Service | Cao M.,Medical Research Service | Mirandola L.,Texas Tech University | Figueroa J.A.,Texas Tech University | And 6 more authors.
PLoS ONE | Year: 2014

The development of gene therapy vectors for treating diseases of the cardiovascular system continues at a steady pace. Moreover, in the field of gene therapy the utility of ''disease-specific promoters'' has strong appeal. Many therapeutic genes, including transforming growth factor beta 1 or interleukin 10, are associated to adverse effects. The use of a disease-specific promoter might minimize toxicity. The lectin-like oxidized low density lipoprotein receptor 1 is a marker of cardiovascular disease and a potential therapeutic target. The lectin-like oxidized low density lipoprotein receptor 1 is known to be upregulated early during disease onset in a number of cell types at the sites where the disease will be clinically evident. In this study an adeno-associated virus-2 DNA vector (AAV2) using the AAV8 capsid, and containing the full length The lectin-like oxidized low density lipoprotein receptor 1 promoter, was generated and assayed for its ability to express human interleukin 10 in low density lipoprotein receptor knockout mice on high cholesterol diet. The cytomegalovirus early promoter was used for comparison in a similarly structured vector. The two promoters were found to have equal efficacy in reducing atherogenesis as measured by aortic systolic blood velocity, aortic cross sectional area, and aortic wall thickness. This is the first head-to-head comparison of a constitutive with a disease-specific promoter in a therapeutic context. These data strongly suggest that the use of a disease-specific promoter is appropriate for therapeutic gene delivery.


Mirandola L.,Texas Tech University Health Sciences Center | Mirandola L.,Kiromic LLC | Wade R.,Texas Tech University Health Sciences Center | Verma R.,Texas Tech University Health Sciences Center | And 9 more authors.
International Reviews of Immunology | Year: 2015

Purpose of the study: Male-based studies, both at the biochemical and at the pre-clinical/clinical trial levels, still predominate in the scientific community. Many studies are based on the wrong assumption that both sexes are fundamentally identical in their response to treatments. As a result, findings obtained mainly in males are applied to females, resulting in negative consequences female patients. In cancer immunotherapy, there is still a scarce focus on this topic. Here we review the main differences in immune modulation and immune system biology between males and females with a particular focus on how these differences affect cancer immunotherapy and cancer vaccines. Methods: We reviewed articles published on PubMed from 1999 to 2014, using the keywords: sex hormones, immune response, estrogen, immunotherapy, testosterone, cancer vaccines, sex-based medicine. We also present new data wherein the expression of the cancer testis antigen, Ropporin-1, was determined in patients with multiple myeloma, showing that the expression of Ropporin-1 was influenced by sex. Results: Male and female immune systems display radical differences mainly due to the immune regulatory effects of sex hormones. These differences might have a dramatic impact on the immunological treatment of cancer. Moreover, the expression of tumor antigens that can be targeted by anti-cancer vaccines is associated with sex. Conclusion: Future clinical trials focusing on cancer immunotherapy will need to take into account the differences in the immune response and in the frequency of target antigen expression between male and females, in order to optimize these anti-cancer immunotherapies of the third millennium. © 2015 Informa Healthcare USA, Inc.

Loading Kiromic LLC collaborators
Loading Kiromic LLC collaborators